REG - Oncimmune Hldgs PLC - Posting of Notice of General Meeting

Oncimmune HoldingsAnnouncement

06/03/2024 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240306:nRSF8744Fa&default-theme=true

RNS Number : 8744F  Oncimmune Holdings PLC  06 March 2024

6 MARCH 2024

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Posting of Notice of General Meeting

 

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company
to the pharmaceutical and biotechnology industry enabling precision medicine,
announces that it has sent a notice of a General Meeting ("GM") to
shareholders, to be held at 10:00am GMT on 2 April 2024 at the offices of
Singer Capital Markets, 1 Bartholomew Lane, London, EC2N 2AX. The principal
purpose of the GM will be to approve the Company's Annual Report and Accounts
for the financial year ended 31 August 2023 ("Annual Report") which was
published on 29 February 2024. The Annual Report and the notice of GM can be
viewed on the "Investors" section of the Company's website at
www.oncimmune.com (http://www.oncimmune.com) .

 

For further information:

 

Oncimmune Holdings plc

contact@oncimmune.com

 

Singer Capital Markets (Nominated Adviser and Broker)

Philip Davies, Harry Gooden, James Fischer

+44 (0)20 7496 3000

 

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune
interactions through the autoantibody profile. Taking a platform approach to
generating insights, Oncimmune is partnering with global pharmaceutical and
biotech companies, as well as contract research organisations (CROs) to
discover novel biomarkers for the development of more targeted and effective
therapies across many immune-mediated diseases. Our mission at Oncimmune is to
enable precision medicine. We help our partners to discover novel biomarkers,
drug targets and predict treatment efficacy through the application of our
platform. We are able to do this by deploying our world class scientific team
and our cutting-edge technology platform, built on years of experience in the
field. Our aim is to make this an essential tool in drug discovery and
development.

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGBUGDXBGGDGSL